Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD9742 · 5 trials · 4 indications
Adverse events, vital signs, electrocardiograms, telemetry, physical exams, and clinical laboratory assessments will be assessed prior to, during, and after treatment
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Single dose of 750mg of intravenous AZD9742 in healthy elderly volunteers |
| 2 | PLACEBO_COMPARATOR | Sterile 5% dextrose solution |
| AZD9742 IV Infusion | EXPERIMENTAL | Active |
| Placebo to AZD9742 IV Infusion | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| AZD9742 | DRUG | Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL |
| Placebo | DRUG | Sterile 5% dextrose solution |
| Diltiazem | DRUG | Orally, daily beginning on Day 4 for 14 consecutive days |
| ketoconazole | DRUG | 200 mg, orally, every 12 hours starting on Day 4 for 10 consecutive days in which on Day 13 only the morning dose will be administered |
| Placebo to match AZD9742 | DRUG | Single IV infusion of AZD9742 placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo) |
Inclusion Criteria: * Male and female volunteers at age of 65 years or older with suitable veins for cannulation or repeated venipuncture, in good health (based on medical history and physical examination and clinical laboratory tests) as judged by the investigator. * Female volunteers must be post...
AZD9742 is an investigational small molecule being studied in healthy volunteers to assess its safety, tolerability, and pharmacokinetics. It is not approved for any disease and remains in Phase 1 clinical development. Studies have evaluated single and multiple intravenous doses, including in Japanese subjects, but no therapeutic indication has been established.
AZD9742 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the NASDAQ under the ticker AZN. The company has sponsored all completed Phase 1 trials of this investigational small molecule.
AZD9742 is in Phase 1 clinical development. All three completed trials are Phase 1 studies, and there are no active trials currently listed. The drug is investigational and has not been approved by regulatory authorities.
AZD9742 has completed four Phase 1 trials: NCT01030224, NCT01064388, NCT01114152, and NCT01124760. These studies evaluated single and multiple ascending doses in healthy subjects, including Japanese participants, and assessed potential drug interactions with diltiazem or ketoconazole.
No alternative names for AZD9742 have been disclosed in the clinical trial records. The compound is identified solely by its code name AZD9742 across all completed studies.